Parent of Tc-99m, Mo-99 is the gamma-emitting workhorse behind ~80% of nuclear medicine diagnostic imaging. Supply is fragile: 8 research reactors make up production capacity, with many reaching the end of their operating lifecycle.

Therapeutic for thyroid cancer and 40–50% of high-risk thyroid disease patients. Facing similar aging supply infrastructure to Mo-99, exacerbating demand challenges.

Beta-emitting therapy for prostate and neuroendocrine cancers, with hundreds of trials underway across many cancers, including breast cancer, lymphoma, and lung cancer. One of the most clinically mature radioisotopes for therapeutic applications.

Alpha-emitting targeted cancer therapy with significant interest across many cancer types, such as prostate, leukaemia, neuroendocrine, and multiple myeloma. Multiple Phase III studies from various pharmaceutical companies are progressing, and establishing commercial-scale production capabilities are key.

Emerging theragnostic isotope, where the diagnostic and therapy are delivered by a single isotope. TB-161 is showing potential to outperform Lu-177. Historic supplies were limited, and ensuring ready access to this radioisotope is key for its continued development as a theragnostic agent.

Used in trials for prostate, breast, and neuroendocrine cancers amongst many other emerging cancer applications. Cu-67 has significant interest as a therapeutic radioisotope, particularly when paired with its sister isotope, Cu-64, already used for diagnostics. Establishing readily available and scalable supply of Cu-67 is key for bringing this new treatment to patients.